Image Alt

Bayer

ePoster P-115 “Sequential treatment with sorafenib followed by regorafenib in patients with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study”

This poster shows data from an interim analysis of the REFINE study, an ongoing, prospective, observational, post-authorization safety study designed to evaluate the safety and effectiveness of sequential treatment with sorafenib followed by regorafenib in patients with unresectable HCC in real-world practice.

ILCA Past Conferences

2019

2018

2017

2016

2015

Contact Us

International Liver Cancer Association (ILCA)
Phone

+32 (0)2 320 2531

Email

Association and Membership Inquiries: [email protected]

Annual Conference Inquiries: [email protected]

Website

www.ilca-online.org

    By using this form you agree to the storage and handling of your data by this website.